Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
Nakasya A, Hagiwara Y, Ikoma T, Kurioka Y, Matsumoto T, Yamamoto Y, Tsuduki T, Kajiwara T, Moriwaki T, Nishina T, Yamashita N, Hyodo I. Nakasya A, et al. Int J Clin Oncol. 2022 Apr;27(4):684-694. doi: 10.1007/s10147-022-02114-y. Epub 2022 Jan 28. Int J Clin Oncol. 2022. PMID: 35089459 Free PMC article.
NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN).
Kajiwara T, Nishina T, Nakasya A, Yamashita N, Yamashita R, Nakamura Y, Shiozawa M, Yuki S, Taniguchi H, Hara H, Ohta T, Esaki T, Shinozaki E, Takashima A, Moriwaki T, Denda T, Ohtsubo K, Sunakawa Y, Horita Y, Kawakami H, Kato T, Satoh T, Ando K, Mizutani T, Yasui H, Goto M, Okuyama H, Yamazaki K, Yoshino T, Hyodo I. Kajiwara T, et al. Among authors: nakasya a. J Cancer Res Clin Oncol. 2022 Oct;148(10):2841-2854. doi: 10.1007/s00432-022-04064-4. Epub 2022 May 27. J Cancer Res Clin Oncol. 2022. PMID: 35622165
Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Hino K, Nishina T, Numata Y, Asagi A, Inoue T, Yoshimatsu M, Sakaguchi C, Nakasya A, Nishide N, Kajiwara T, Terao T, Nadano S, Marui K, Okujima Y, Kokubu M, Imamura Y, Kanemitsu K, Koizumi M, Kumagi T, Hiasa Y, Hyodo I. Hino K, et al. Among authors: nakasya a. Intern Med. 2022;61(15):2255-2261. doi: 10.2169/internalmedicine.8736-21. Epub 2022 Aug 1. Intern Med. 2022. PMID: 35908959 Free PMC article.
Risk factors and efficacy outcomes of early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab in advanced gastric cancer: a multicenter retrospective cohort study.
Hagiwara Y, Nakasya A, Matsumoto T, Ikoma T, Yamamoto Y, Kurioka Y, Tsuduki T, Kajiwara T, Nishina T, Yamashita N, Moriwaki T, Hyodo I. Hagiwara Y, et al. Among authors: nakasya a. J Gastrointest Oncol. 2022 Dec;13(6):2769-2778. doi: 10.21037/jgo-22-499. J Gastrointest Oncol. 2022. PMID: 36636083 Free PMC article.